IN THE NEWS - oncohost

Media Coverage

06/07/2021

Oncohost’s Focus on the Patient Offers Precision Oncology To Combat Cancer

22/06/2021

Oncohost opens trial sites for study evaluating its AI proteomics profiling technology

17/06/2021

NHS Opens Eight UK Clinical Trial Sites to Assess Cancer Patient Response to Immunotherapy in Collaboration with OncoHost

17/06/2021

Israel’s OncoHost, UK’s NHS to study cancer patient responses to immunotherapies

To all Media Coverage >

News Releases

16/06/2021

NHS Opens Eight UK Clinical Trial Sites to Assess Cancer Patient Response to Immunotherapy in Collaboration with OncoHost

OncoHost's AI-Based Proteomic Profiling Platform, PROphet®, to Serve Key Role in Host Response Evaluation of Late-Stage Disease Patients

19/01/2021

OncoHost Secures $8 Million Series B Funding Round to Advance its AI-Powered Precision Oncology Platform

On a Mission to Match Individual Cancer Patients with the Most Effective Treatment, Investment will Expand Clinical Trials, Support Opening of a US Office and Preparation for Commercial Launch

11/01/2021

OncoHost Welcomes Nobel Prize Winner to Scientific Advisory Board

Prof. Aaron Ciechanover Joins Host Response Profiling Company to Improve Precision Oncology and Overcome Resistance to Cancer Treatments

09/11/2020

OncoHost to Present Data on Predicting Host Response to Immunotherapy in Melanoma Patients at SITC 2020

Study Examines Plasma-Based Proteomic Profiling as a Clinically Insightful Tool for Oncologists to Identify New Targets in Overcoming Treatment Resistance

To all News Releases >